{"schema_version":"secwatch.filing_event.v1","accession":"0001701541-25-000029","form_type":"8-K","ticker":"BDTX","cik":"0001701541","company_name":"Black Diamond Therapeutics, Inc.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.707997+00:00","generated_at":"2026-05-17T17:51:03.671573+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Black Diamond completes Phase 2 enrollment for silevertinib; net loss narrows to $10.6M","bullets":["Cash $142.8M (vs $98.6M Dec 2024) funds operations into Q4 2027.","Net loss $10.6M in Q2 2025 vs $19.9M in Q2 2024; R&D expenses down to $9.3M.","Phase 2 trial of silevertinib in 1L non-classical EGFRm NSCLC fully enrolled (n=43); ORR & preliminary DOR data expected Q4 2025.","Exploring partnership opportunities for silevertinib in NSCLC and GBM; FDA meeting planned for 1H 2026 on registrational path."],"urls":{"canonical":"https://secwatch.observer/filing/0001701541-25-000029","json":"https://secwatch.observer/filing/0001701541-25-000029.json","markdown":"https://secwatch.observer/filing/0001701541-25-000029.md","text":"https://secwatch.observer/filing/0001701541-25-000029.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701541/000170154125000029/0001701541-25-000029-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701541/000170154125000029/bdtx-20250807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T17:51:03.671573+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}